Coherus Oncology
CHRS
128 hedge funds and large institutions have $79.9M invested in Coherus Oncology in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 42 increasing their positions, 32 reducing their positions, and 22 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 32
13% more call options, than puts
Call options by funds: $78K | Put options by funds: $69K
5% less funds holding
Funds holding: 135 → 128 (-7)
5.19% less ownership
Funds ownership: 71.98% → 66.79% (-5.2%)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
44% less capital invested
Capital invested by funds: $143M → $79.9M (-$62.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.78M |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$1.23M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.1M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
+$988K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$971K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
-$10.1M |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
-$1.45M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.03M |
| 4 |
Morgan Stanley
New York
|
-$1M |
| 5 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$919K |
CHRS Hedge Fund Activity: Q3 2024 in Review
128 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2024, worth a combined $79.9M — down 44% from $143M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CHRS and 16 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 42 added.
The largest buyer was Tang Capital Management, adding an estimated $1.78M. The largest seller was Temasek Holdings, exiting entirely with an estimated $10.1M sold.
- 128 institutional investors held Coherus Oncology (CHRS) as of Q3 2024, down from 135 in Q2 2024.
- Funds reported $79.9M of Coherus Oncology stock for Q3 2024, down 44% quarter-over-quarter.
- 16 funds opened new Coherus Oncology positions in Q3 2024 and 22 closed out, a net change of -6 holders.
- The largest Coherus Oncology buyer in Q3 2024 was Tang Capital Management, an estimated $1.78M added.
- The largest Coherus Oncology seller in Q3 2024 was Temasek Holdings, an estimated $10.1M sold.
Based on aggregated 13F filings for Q3 2024.